CA
NZ
UK
AU
IND
US
BIO-RAD LABORATORIES, INC. (NYSE: BIO) recorded option exercises covering 320 shares at $0 per share in transactions dated 5 September 2026 and 6 September 2026. Allison Schwartz, a director, held 1,768 shares after those exercises.
The transaction left him with 2,631 shares, representing about 65.1% of his resulting shares holding.
Butterfly Network, Inc. (NYSE: BFLY) finance executive Megan Carlson sold 13,804 shares at $7.30 per share on 4 September 2026. Following the transaction, Carlson owned 412,085 shares.
Its September 2026 investor presentation highlights clinical progress for aglatimagene besadenovec and linoserpaturev, two programs designed to support cancer treatment development.
The event gives investors access to a live webcast through the company’s investor website as Cardiol (NASDAQ: CRDL) advances therapies for inflammatory and fibrotic heart disease.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) President and CEO Barber Daniel recorded a code X transaction involving 91,743 shares at $0.96 per share on September 8, 2026. His resultingEquityposition stood at 677,317 shares. Barber’s resulting derivative securities position was 0.
The changes became effective on September 2 afterShareholderapproval on August 25 and registration confirmation from the Cayman Islands Registrar of Companies on September 7.
RoyaLand Co Ltd. (OTC: RLNDF) is advancing Savoia 1908 FC’s professional-football project with a squad valued at approximately €3.88 million and a stated objective of securing its position in Serie C. The BermudaHolding Companysays the club’s longer-term strategy is to develop young players, build …
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares were sold by Chief Operating Officer Neervannan Seshadri at $85 per share, with 4,564 shares changing hands.
TAT TECHNOLOGIES LTD (NASDAQ: TATT) received approval for every proposal presented at its 2026 annual general meeting, with approximately 72% of its outstanding ordinary shares represented and voted. The meeting outcome covers the proposals included in the company’s proxy materials.
Please wait processing your request...